Notice of Results, Analyst & Investor Presentation
N4 Pharma PLC will release its unaudited interim results for the six months ending June 30, 2025, on Thursday, September 25, 2025. An online analyst briefing, hosted by the Chief Executive Officer, will take place at 9:30 am on the same day to review these results. Following the briefing, an investor presentation covering the interim results will be held at 2:00 pm, open to existing and potential shareholders.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, will announce its unaudited interim results for the six months ended 30 June 2025 on Thursday, 25 September 2025 and hold the following analyst briefing and investor presentation.
Analyst briefing
An online briefing for analysts will be hosted by Nigel Theobald, Chief Executive Officer, at 9.30 am on Thursday, 25 September 2025, to review the interim results. Analysts wishing to attend should contact Sarah Hollins at Northstar Communications at sarah@northstarcommunications.co.uk.
Investor presentation
An investor presentation to cover the interim results will be held at 2.00 pm on Thursday, 25 September 2025.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 am on Wednesday, 24 September 2025 or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet N4 Pharma plc via:
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Submit your questions directly to the management team via the N4 Pharma Investor Hub | Via N4 Pharma Investor Hub: investors.n4pharma.com https://n4pharma.com/link/y05doe |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Limited Investor Relations Sarah Hollins | Tel: +44 (0)113 730 3896 |
About N4 Pharma
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.